Zobrazeno 41 - 50
of 199
pro vyhledávání: '"Ragini R. Kudchadkar"'
Autor:
William J. Fulp, Jeffrey S. Weber, Ricardo J. Gonzalez, Geoffrey T. Gibney, Jonathan S. Zager, Vernon K. Sondak, Sangeetha Prabhakaran, Ragini R. Kudchadkar
Publikováno v:
The American Surgeon. 82:1109-1116
The prognosis of patients with gastrointestinal (GI) melanoma metastases is poor. Surgery renders select patients disease free and/or palliates symptoms. We reviewed our single-institution experience of resection with GI melanoma metastases. A retros
Publikováno v:
Journal of Immunotherapy. 39:355-366
Th17 cells represent a distinct subset of CD4 effector T cells with potent pathogenic qualities, capable of directly mediating tumor cell destruction. IL-2 has frequently been shown to have a negative effect on Th17 differentiation while supporting r
Publikováno v:
Melanoma Research. 26:535-539
High-dose IL-2 (HDIL-2) is associated with complete and durable responses in only 5-10% of patients with stage intravenous melanoma and the toxicity profile is significant. In-vivo human models have recently shown a stimulatory effect of exogenous IL
Autor:
Martin A. Cheever, Steven P. Fling, Blanca Homet Moreno, Nirasha Ramchurren, Andrew S. Brohl, Thomas Olencki, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Kim Margolin, Lisa Lundgren, Brian C. Boulmay, Harriet M. Kluger, Candice D. Church, Melissa Amber Burgess, Michi M. Shinohara, Suzanne L. Topalian, Bob Salim, Song Youn Park, Janis M. Taube, Paul Nghiem, Sunil Reddy, Nageatte Ibrahim, Steven R. Bird, Ragini R. Kudchadkar, Adam I. Riker, Abha Soni, Brent A. Hanks, Elad Sharon, Adil Daud, Phillip A. Friedlander
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 9
PURPOSE Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for advanced MCC (aMCC) demonstrate increased progression-free survival (PFS)
Autor:
Steven P. Fling, Daniel L. Barber, Vanessa Raabe, Paul Nghiem, David Ashkin, Ragini R. Kudchadkar, Jonathan Cheng, Tracey A. Day, Shunsuke Sakai, Julie Vergara, Martin A. Cheever, Elad Sharon, Lisa Lundgren, Jorge Nieva, Colleen S. Kraft
Publikováno v:
Sci Transl Med
Because of the well-established therapeutic benefit of boosting antitumor responses through blockade of the T cell inhibitory receptor PD-1, it has been proposed that PD-1 blockade could also be useful in infectious disease settings, including Mycoba
Autor:
Christina Wu, R. Donald Harvey, Colleen Lewis, Bassel F. El-Rayes, Mehmet Akce, Viraj A. Master, Meredith R Kline, Olatunji B. Alese, Bradley C. Carthon, Yuan Liu, David H. Lawson, Haydn T. Kissick, Walid L. Shaib, Dylan J. Martini, Taofeek K. Owonikoko, Conor E. Steuer, Julie M. Shabto, Ragini R. Kudchadkar, Suresh S. Ramalingam, Mehmet Asim Bilen, Hannah Collins, Rathi N. Pillai
Publikováno v:
Invest New Drugs
Background Given the increasing number of available immunotherapeutic agents, more patients are presenting after failing immunotherapy in need of new treatment options. In this study, we investigated the clinical outcomes of patients treated with seq
Autor:
Ragini R. Kudchadkar, Dylan J. Martini, Conor E. Steuer, R. Donald Harvey, Colleen Lewis, Viraj A. Master, Mehmet Akce, Haydn T. Kissick, Bassel F. El-Rayes, Mehmet Asim Bilen, Olatunji B. Alese, Walid L. Shaib, Bradley C. Carthon, Taofeek K. Owonikoko, Yuan Liu, David H. Lawson, Hannah Collins, Christina Wu, Julie M. Shabto, Suresh S. Ramalingam
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Background Selecting the appropriate patients to receive immunotherapy (IO) remains a challenge due to the lack of optimal biomarkers. The presence of liver metastases has been implicated as a poor prognostic factor in patients with metastatic cancer
Publikováno v:
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 38
In this article, we will focus on the practice-changing developments for stage III melanoma, from the use of the sentinel node (SN) biopsy to complete lymph node dissection (CLND) and upcoming adjuvant therapies. MSLT-1 (Multicenter Selective Lymphad
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 25(5)
Immunotherapy treatments in oncology have garnered much attention and use throughout the past several years. With increased use and new approvals in many different types of solid tumors and hematological malignancies, practitioners in oncology should
Autor:
Anna C. Pavlick, Reena Thomas, Peter A. Forsyth, Hussein Abdul-Hassan Tawbi, F. Stephen Hodi, David A. Reardon, Omid Hamid, Karl D. Lewis, Joel Jiang, Alain Algazi, Michael B. Atkins, Sheena Demelo, Kim Margolin, Marc S. Ernstoff, Igor Puzanov, Christopher D. Lao, Ahmad A. Tarhini, Stergios J. Moschos, Ragini R. Kudchadkar, Nikhil I. Khushalani, Alexandre Avila, Michael A. Postow
Publikováno v:
The New England journal of medicine, vol 379, iss 8
BackgroundBrain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melanoma. Previous studies of nivolumab combined with ipilimumab in metastatic melanoma have excluded patients with untreated br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9842d318557841dc70e5ef68e3840d40
https://escholarship.org/uc/item/41x6h654
https://escholarship.org/uc/item/41x6h654